Consistent OS Efficacy Benefit Across Multiple Treatment Subgroups Demonstrates IMNN-001’s Ability to Recruit a Powerful Anti-Cancer Immune Response Results, presented simultaneously in oral presentation at ASCO 2025 and in peer-reviewed Gynecologic Oncology, suggest very meaningful survival effect of IMNN-001 in women HRP and HRD positive, including those with BRAC1 and BRCA2 mutations LAWRENCEVILLE, N.J., June 03, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 ...

Toronto, ON, June 03, 2025 (GLOBE NEWSWIRE) -- Summer in Canada is a season of endless possibilities when memories are made, stories unfold, and the spirit of exploration comes alive. From the misty shores of British Columbia to the rugged coastlines of the Atlantic, Days Inn is your ultimate gateway to unforgettable experiences from coast to coast. Travellers can unlock extraordinary adventures that capture the heart and spirit of Canadian summer, with conveniently located hotels serving as the perfect hom ...

Azurion_SmartCT_Dual_viewer SmartCT-Soft-Tissue-Dual-Phase-Cerebral-Stroke Demonstrated at LINNC Paris 2025, the company’s latest release of SmartCT delivers fast, intelligent 3D imaging in the Angio suite — helping physicians act with greater speed and confidence during a range of critical neurovascular procedures Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the CE-marking of its latest SmartCT image reconstruction soluti ...

To Nasdaq Copenhagen A/S Executive ManagementBernstorffsgade 40DK-1577 København Vwww.rd.dkTelephone +45 7012 53003 June 2025 Company Announcement number 48/2025 Extraordinary general meeting of Realkredit Danmark A/S Realkredit Danmark A/S will hold an extraordinary general meeting on the 4 June 2025 at 10.00 am at Bernstorffsgade 40, 1577 København V, with the following agenda: Proposal for the election of the Head of Wholesale Credit and LC&I Risk Management, Claus Schrøder Jensen, to the company’s Board ...

Core Viewpoint - Chemomab Therapeutics has secured new patent protections for its lead product nebokitug in China and Russia, enhancing its intellectual property portfolio and positioning for future commercialization in the treatment of primary sclerosing cholangitis (PSC) [1][2][3] Patent Protections - The State Intellectual Property Office of China issued Patent No. ZL 2018 8 0018207.8, which protects the use of nebokitug in hepatic diseases, including PSC, with coverage extending to 2038 [2] - The Federal Service for Intellectual Property of Russia granted RU Patent 2022125176, which covers various formulations and doses of nebokitug, providing protection until 2041 [3] Clinical Development and Regulatory Pathway - Positive data from the Phase 2 SPRING trial of nebokitug has established a promising clinical profile for treating PSC, which is a debilitating disease with no effective treatments [2] - The FDA has outlined a clear pathway for regulatory approval of nebokitug in PSC, which is significant for the company's future plans [2] - Chemomab is preparing for a potential Phase 3 registrational trial for nebokitug in PSC, following the positive results from earlier trials [6] Company Overview - Chemomab Therapeutics is a clinical-stage biotechnology company focused on developing innovative therapeutics for fibro-inflammatory diseases, with nebokitug being a first-in-class dual activity monoclonal antibody targeting CCL24 [6] - The company has reported positive results from four clinical trials of nebokitug, demonstrating a favorable safety profile and potential for treating severe fibro-inflammatory diseases [6]

Advanced Security Solutions Extend Zero Trust Everywhere to Protect Data Across Branches, Multi-Cloud Environments, and Remote EnvironmentsLAS VEGAS, June 03, 2025 (GLOBE NEWSWIRE) -- Zenith Live Las Vegas — Zscaler, Inc. (NASDAQ: ZS), the leader in cloud security, today announced a new suite of solutions that enable customers to quickly adopt Zero Trust Everywhere. These innovations extend the reach of true Zero Trust and enable businesses to modernize and scale securely by providing end-to-end segmentatio ...

DALLAS, June 03, 2025 (GLOBE NEWSWIRE) -- Westwood Holdings Group (NYSE: WHG), a boutique asset management, trust and wealth services firm, today announced the appointment of Jan Ryan to its Board of Directors. Based in Austin, Texas, Ms. Ryan brings over three decades of leadership experience, spanning technology, venture capital, revenue strategy and operational alignment. Her appointment further strengthens Westwood’s Board as the firm continues to advance its focus on innovation, client experience and l ...

SPRINGFIELD, N.J., June 03, 2025 (GLOBE NEWSWIRE) -- Village Super Market, Inc. (NSD-VLGEA) today reported its results of operations for the third quarter ended April 26, 2025. Third Quarter Highlights Net income of $11.2 million, an increase of 24% compared to $9.0 million in the third quarter of the prior yearAdjusted net income of $11.6 million, an increase of 21% compared to adjusted net income of $9.6 million in the third quarter of the prior yearSales increased 3.2% and same store sales increased 1.9% ...

LAFAYETTE, La., June 03, 2025 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the “Company” or “Viemed”) (NASDAQ:VMD), a national leader in respiratory care and technology-enabled home medical equipment services, today announced it will present at the East Coast IDEAS Investor Conference on Wednesday June 11, 2025 at The Westin Times Square in New York, NY. Viemed’s presentation is scheduled to begin at 11:30am ET. The presentation is webcast and can be accessed through the conference host’s main website: http ...

Core Viewpoint - The company has postponed its first quarter 2025 earnings release and call due to a recent security incident affecting its IT systems, although preliminary financial results indicate strong performance exceeding prior guidance ranges [2][5][6]. Financial Performance - Preliminary net sales for the first quarter of 2025 are expected to be $1.35 billion, surpassing the prior guidance of $1.30 billion to $1.33 billion [8]. - Adjusted operating income is projected at $32 million, exceeding the previous guidance of $10 million to $30 million [8]. - Adjusted diluted earnings per share (EPS) is anticipated to be $0.09, compared to a prior range of ($0.10) to $0.10 [8]. Security Incident - On May 24, 2025, the company detected a security incident and initiated response protocols to contain unauthorized access [3]. - Corporate systems and the e-commerce website were temporarily shut down on May 26, 2025, with the website restored by May 29, 2025 [4]. - The incident has not materially disrupted operations but has led to expenses that may impact future financial results [6]. Operational Impact - The restoration process has limited employee access to necessary systems for financial reporting, resulting in the postponement of the earnings release [5]. - The company continues to assess the full scope and impact of the incident under the oversight of the Audit Committee [6].